{"id":1421,"date":"2010-02-01T17:48:14","date_gmt":"2010-02-01T22:48:14","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/monday-february-1-news-update-stent-comparison-herbal-products-prostate-cancer-therapy\/"},"modified":"2011-07-19T17:45:05","modified_gmt":"2011-07-19T21:45:05","slug":"monday-february-1-news-update-stent-comparison-herbal-products-prostate-cancer-therapy","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/02\/01\/monday-february-1-news-update-stent-comparison-herbal-products-prostate-cancer-therapy\/","title":{"rendered":"Monday February 1 News Update: Stent Comparison, Herbal Products, Prostate Cancer Therapy"},"content":{"rendered":"<p><strong>ENDEAVOR IV:<\/strong> One-year results of the ENDEAVOR IV trial <a href=\"http:\/\/content.onlinejacc.org\/cgi\/content\/abstract\/55\/6\/543\">comparing zotarolimus-eluting stents (ZES) and paclitaxel-eluting stents (PES)<\/a> have been published in the <em>Journal of the American College of Cardiology<\/em>. Martin Leon et al conclude that ZES &#8220;has improved periprocedural safety, similar 12-month clinical safety and efficacy outcomes, and despite more frequent angiographic restenosis, similar clinical repeat revascularization events.&#8221; But in an accompanying editorial comment E Magnus Ohman and Robert Califf write about the difficulties of applying the results of comparative trials of drug-eluting stents to clinical practice. They go on to explore the weaknesses of different trial designs and note that &#8220;rational and intelligent people often will value different parts of a composite end point in different ways.&#8221;<\/p>\n<p><strong>Stent Patent Dispute Settled:<\/strong> <a href=\"http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=62272&amp;p=irol-newsArticle&amp;ID=1381150&amp;highlight=\">Boston Scientific announced today<\/a> that it had settled three patent disputes with stent rival Johnson &amp; Johnson for $1.72 billion.<\/p>\n<p><strong>Herbal Products:<\/strong> Millions of Americans with cardiovascular disease use herbal products in addition to (or instead of) prescription medications, often without telling their physicians. Arshad Jahangir and colleagues <a href=\"http:\/\/content.onlinejacc.org\/cgi\/content\/abstract\/55\/6\/515\">review the use of herbal products in patients with cardiovascular disease<\/a> in the <em>Journal of the American College of Cardiology<\/em>, noting the &#8220;clear need for better public and physician&nbsp;understanding of herbal products through health education,&nbsp;early detection and management of herbal toxicities, scientific&nbsp;scrutiny of their use, and research on their safety and&nbsp;effectiveness.&#8221;<\/p>\n<p><strong>Prostate Cancer Therapy:<\/strong> Androgen-deprivation therapy (ADT) for prostate cancer may increase cardiovascular risk. The relationship has not been definitively established, but physicians are not sufficiently aware of the association, according to <a href=\"http:\/\/circ.ahajournals.org\/cgi\/content\/abstract\/CIRCULATIONAHA.109.192695v1\">a scientific advisory <\/a>published in <em>Circulation<\/em> from the American Heart Association, the American Cancer Society, the American Urological Association and the American Society for Therapeutic Radiology and Oncology.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ENDEAVOR IV: One-year results of the ENDEAVOR IV trial comparing zotarolimus-eluting stents (ZES) and paclitaxel-eluting stents (PES) have been published in the Journal of the American College of Cardiology. Martin Leon et al conclude that ZES &#8220;has improved periprocedural safety, similar 12-month clinical safety and efficacy outcomes, and despite more frequent angiographic restenosis, similar clinical [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1421","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1421"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1421\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}